Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Oak Bay Biosciences is a new biotechnology company – with a portfolio of patents, molecules, and preclinical data – with the goal to bring the first therapy for Stargardt disease to market. Stargardt disease affects approximately 800,000 individuals worldwide and causes progressive, irreversible blindness – often beginning in childhood. Oak Bay Biosciences' lead molecule could prevent blindness for the lifetime of a pati...
Oak Bay Biosciences is a new biotechnology company – with a portfolio of patents, molecules, and preclinical data – with the goal to bring the first therapy for Stargardt disease to market. Stargardt disease affects approximately 800,000 individuals worldwide and causes progressive, irreversible blindness – often beginning in childhood. Oak Bay Biosciences' lead molecule could prevent blindness for the lifetime of a patient due to high potency, durability, and extended half-life in the eye. Oak Bay Biosciences' business model is based on efficient and rapid progress to the clinic.

List your booth number for exhibitions, ask us